Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q4 EPS of ($0.75), $0.07 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $13.28 million versus the consensus estimate of $14.91 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised
• Canaccord Reiterates Buy Rating on Achieve Life Sciences (ACHV)
• Definium Therapeutics Inc (DFTX) PT Raised to $50 at Needham